Literature DB >> 29763618

Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Martin Früh1, Solange Peters2.   

Abstract

In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29763618     DOI： 10.1016/j.ccell.2018.04.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  5 in total

Review 1.  Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

Authors:  Roman M Chabanon; Gareth Muirhead; Dragomir B Krastev; Julien Adam; Daphné Morel; Marlène Garrido; Andrew Lamb; Clémence Hénon; Nicolas Dorvault; Mathieu Rouanne; Rebecca Marlow; Ilirjana Bajrami; Marta Llorca Cardeñosa; Asha Konde; Benjamin Besse; Alan Ashworth; Stephen J Pettitt; Syed Haider; Aurélien Marabelle; Andrew Nj Tutt; Jean-Charles Soria; Christopher J Lord; Sophie Postel-Vinay
Journal:  J Clin Invest       Date:  2019-02-11       Impact factor: 14.808

3.  Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.

Authors:  Pham Nguyen Quy; Masashi Kanai; Keita Fukuyama; Tadayuki Kou; Tomohiro Kondo; Yoshihiro Yamamoto; Junichi Matsubara; Akinori Hiroshima; Hiroaki Mochizuki; Tomohiro Sakuma; Mayumi Kamada; Masahiko Nakatsui; Yuji Eso; Hiroshi Seno; Toshihiko Masui; Kyoichi Takaori; Sachiko Minamiguchi; Shigemi Matsumoto; Manabu Muto
Journal:  Oncologist       Date:  2019-06-11

4.  Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas.

Authors:  Changzheng Wang; Han Liang; Cong Lin; Fuqiang Li; Guoyun Xie; Sitan Qiao; Xulian Shi; Jianlian Deng; Xin Zhao; Kui Wu; Xiuqing Zhang
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

5.  Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma.

Authors:  Alejandro García; Gonzalo Recondo; Martín Greco; Máximo de la Vega; Florencia Perazzo; Gonzalo Recondo; Alejandra Avagnina; Valeria Denninghoff
Journal:  Heliyon       Date:  2020-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.